Investigational drug · Phase 2
NIO752
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "NIO752"
First trial start
2026
Oct 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NIO752", any sponsor or status.
Conditions studied
As listed on its trial records.
- Progressive Supranuclear Palsy
- Corticobasal Degeneration
- Frontotemporal Lobar Degeneration
- Tauopathies
Largest trials
Live from ClinicalTrials.gov: studies naming "NIO752" as an intervention, largest first.
- A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear PalsyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07498426 · 300 participants (planned) · Start Jun 3, 2026 · Primary completion Jul 20, 2029
Drug: Placebo · For: Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Sites: Scottsdale, Arizona; San Francisco, California; Englewood, Colorado · 64 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04539041 · 59 participants · Start Feb 16, 2021 · Primary completion Oct 17, 2024
Drug: antisense oligonucleotide; placebo · For: Progressive Supranuclear Palsy (PSP)
Sites: La Jolla, California; Rochester, Minnesota; Nashville, Tennessee · 12 sites in all
- A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary TauopathiesNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07868328 · 48 participants (planned) · Start Oct 23, 2026 · Primary completion Mar 26, 2029
Drug: NIO752; Placebo · For: Progressive Supranuclear Palsy; Corticobasal Degeneration; Frontotemporal Lobar Degeneration and 1 more
- Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05469360 · 38 participants · Start Feb 23, 2023 · Primary completion Jul 30, 2026
Drug: NIO752; NIO752 and 5 more · For: Alzheimer Disease; Mild Cognitive Impairment
Sites: Kuopio, Finland; Turku, Finland; Lille, France · 10 sites in all
- A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILKRecruiting
University College, LondonAcademic, hospital or other
NCT06372821 · 10 participants (planned) · Start Nov 18, 2024 · Primary completion Jul 2026
Drug: NIO752 · For: Alzheimer Disease; Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder); Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder) and 1 more
Sites: St Louis, Missouri; London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Progressive Supranuclear Palsy
- TertomotideGV1001Phase 33 trials
GemVax & Kael · Moderate to Severe Alzheimer's Disease, Mild to Moderate Alzheimer's Disease, Progressive Supranuclear Palsy
- AMX0035Phase 32 trials
Amylyx Pharmaceuticals Inc. · Wolfram Syndrome, Progressive Supranuclear Palsy, PSP
- FNP-223Phase 21 trial
Ferrer Internacional S.A. · Progressive Supranuclear Palsy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.